Results of Gynecologic Oncology Group (GOG) 229 K: A phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma von Sill, M, Schilder, J.M, McGonigle, K.F, Rahman, Z, Miller, D.S, Mutch, D.G, Leslie, K.K

Volltext

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group (GOG) study von Bender, D.P, Sill, M, Lankes, H, Darus, C.J, Delmore, J, Rotmensch, J, Gray, H.J, Mannel, R.S, Schilder, J.M, Leslie, K.K, Reyes, H.D, Hunter, M, McCourt, C.K, Samuelson, M

Volltext

Wound morbidity of groin node dissection performed after radiation for vulvar cancer von Schilder, J.M, Hamed, A. Hassan, Mi, D, Rossi, E.C, de Leon, M.C.B, Del Priore, G, Stehman, F.B

Volltext

The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in... von van Keimpema, Martine, Grüneberg, Leonie J, Schilder-Tol, Esther J M, Oud, Monique E C M, Beuling, Esther A, Hensbergen, Paul J, de Jong, Johann, Pals, Steven T, Spaargaren, Marcel

Volltext

789P Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study von Backes, F., Boyle, T., Perhanidis, J., Lim, J., Hartman, J., Schilder, J.M., Hurteau, J., Golembesky, A., Salani, R.

Volltext

745P Ovarian Cancer Retrospective European (O’CaRE) observational study to assess burden of disease and time to next treatment in real-world clinical practice: Results from the Uni... von McGrane, J., Shaw, D., Anand, A., Madhuri, T.K., Krell, J., Saunders, L., Hawkes, C., Schilder, J.M., York, W., Astrom, J.

Volltext

B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains von Slot, Linda M, Hoogeboom, Robbert, Smit, Laura A, Wormhoudt, Thera A.M, Biemond, Bart J, Oud, Monique E.C.M, Schilder-Tol, Esther J.M, Mulder, André B, Jongejan, Aldo, van Kampen, Antoine H.C, Kluin, Philip M, Guikema, Jeroen E.J, Bende, Richard J, van Noesel, Carel J.M

Volltext

43P Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study von Coleman, R.L., Salani, R., Boyle, T., Perhanidis, J., Lim, J., Kalilani, L., Schilder, J.M., Hurteau, J., Golembesky, A., Backes, F.

Volltext

breast cancer, early stage Interim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with HR + /HER2- breast cancer (BC) von Hurvitz, S., Abad, M.F., Rostorfer, R., Chan, D., Egle, D., Huang, C.-S., Barriga, S., Costigan, T.M., Caldwell, C.W., Schilder, J.M., Press, M.F., Slamon, D., Martin, M.

Volltext

Results of Gynecologic Oncology Group (GOG) 229K: A phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma von Dizon, D.S., Sill, M., Schilder, J.M., McGonigle, K.F., Rahman, Z., Miller, D.S., Mutch, D.G., Leslie, K.K.

Volltext

High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma von Kraan, W, van Keimpema, M, Horlings, H M, Schilder-Tol, E J M, Oud, M E C M, Noorduyn, L A, Kluin, P M, Kersten, M J, Spaargaren, M, Pals, S T

Volltext

Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations von Minderman, Marthe, Amir, Avital, Kraan, Willem, Schilder-Tol, Esther J.M., Oud, Monique E.C.M., Scheepstra, Cornelis G., Noorduyn, Arnold L., Kluin, Philip M., Kersten, Marie José, Spaargaren, Marcel, Pals, Steven T.

Volltext

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites von Kraan, W, Horlings, H M, van Keimpema, M, Schilder-Tol, E J M, Oud, M E C M, Scheepstra, C, Kluin, P M, Kersten, M J, Spaargaren, M, Pals, S T

Volltext

The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer von BARLOW, T.S., PRZYBYLSKI, M., SCHILDER, J.M., MOORE, D.H., LOOK, K.Y.

Volltext

Illegitimate WNT Pathway Activation by β-Catenin Mutation or Autocrine Stimulation in T-Cell Malignancies von GROEN, Richard W. J, OUD, Monique E. C. M, SCHILDER-TOL, Esther J. M, OVERDIJK, Marije B, TEN BERGE, Derk, NUSSE, Roel, SPAARGAREN, Marcel, PALS, Steven T

Volltext

Signaling through CD44 Is Mediated by Tyrosine Kinases von Taher, Taher Elamin I., Smit, Linda, Griffioen, Arjan W., Schilder-Tol, Esther J.M., Borst, Jannie, Pals, Steven T.

Volltext

Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis von ATEN, J, ROOS, A, CLAESSEN, N, SCHILDER-TOL, E. J. M, TEN BERGE, I. J. M, WEENING, J. J

Volltext

Reply von Hurteau, Jean A., Roth, L.M., Schilder, J.M., Summers, J.

Volltext

Complete Hydatidiform Mole Coexisting with a Twin Live Fetus: Clinical Course von Hurteau, J.A., Roth, L.M., Schilder, J.M., Sumners, J.

Volltext

Strong expression of CD134 (OX40), a member of the TNF receptor family, in a T helper 2-type cytokine environment von Roos, Anja, Schilder‐Tol, Esther J. M., Weening, Jan J., Aten, Jan

Volltext